Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Polyarteritis nodosa

Rheumatology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Mesenteric, renal, cardiac or limb ischaemia

Severe abdominal pain, peritonism, gastrointestinal bleeding, malignant hypertension, myocardial injury, mononeuritis with rapid weakness or threatened limb indicates organ-threatening medium-artery disease.

Action: Admit, stabilise circulation and pressure, obtain CTA or catheter angiography and surgical or vascular input, test hepatitis B urgently, and start high-dose glucocorticoid plus cyclophosphamide for severe non-viral PAN after cultures and tissue planning.

Synopsis

Recognise polyarteritis nodosa as a medium-artery necrotising vasculitis causing renal, gastrointestinal, skin, nerve and testicular ischaemia, distinguish it from small-vessel ANCA disease, and coordinate angiographic, biopsy and hepatitis-directed treatment.

  • PAN is necrotising vasculitis of muscular medium and small arteries, producing renal-vascular, gastrointestinal, skin, nerve, muscle and testicular ischaemia without primary glomerulonephritis or pulmonary capillaritis.
  • Look for fever, weight loss, livedo, tender nodules, ulcers, myalgia, mononeuritis multiplex, severe hypertension, abdominal pain after meals, GI bleeding and testicular pain.
  • Urinalysis is often bland or shows non-glomerular abnormalities; red-cell casts or pulmonary haemorrhage should redirect toward AAV, anti-GBM or immune-complex disease.
  • Test HBsAg, anti-HBc and HBV DNA early because HBV-associated PAN needs antiviral-led specialist treatment and limited rather than prolonged immunosuppression.
  • Use CTA or MRA to identify renal, mesenteric and hepatic stenoses, occlusions, infarcts and microaneurysms; catheter angiography is the anatomical reference when intervention or high-resolution assessment is required.
  • Biopsy accessible symptomatic skin, muscle, nerve or testis when safe, seeking transmural necrotising arteritis and avoiding blind sampling of unaffected tissue.
  • Severe idiopathic PAN receives high-dose glucocorticoid plus cyclophosphamide; non-severe disease may use glucocorticoid with another steroid-sparing agent under specialist care.
  • HBV-PAN treatment combines potent antiviral therapy, a short glucocorticoid course and often plasma exchange in expert care, avoiding prolonged immunosuppression that sustains viral replication.
  • Manage mesenteric infarction, aneurysm rupture, coronary disease and critical limb ischaemia with surgical, interventional and vascular teams in parallel.
  • ANCA testing is usually negative and not a diagnostic criterion; diagnosis rests on the medium-artery phenotype, imaging or biopsy and exclusion of infection and mimics.

Key red flags

Severe pain out of proportion, guarding, lactate rise or GI bleeding may indicate mesenteric infarction or perforation and requires immediate surgical and vascular imaging.

Abrupt hypertension, AKI or flank pain suggests renal-artery ischaemia or infarction; glomerular casts instead argue against classic PAN.

New foot or wrist drop with painful asymmetric deficits indicates nerve infarction and needs urgent disease control.

Chest pain, troponin rise, arrhythmia or heart failure may indicate coronary arteritis and requires acute cardiology.

HBsAg positivity changes treatment toward antiviral and specialist immune-complex management rather than prolonged conventional immunosuppression alone.

Mesenteric ischaemia

Postprandial or severe acute abdominal pain, bleeding and peritonism signals bowel arterial injury and possible infarction.

Mononeuritis multiplex

Painful asymmetric sensory loss followed by foot or wrist drop reflects sequential nerve-artery infarction.

Investigation priorities

01
FBC, CRP or ESR, renal, liver, CK and urinalysisFirst step

Assess inflammation, ischaemic organ injury and whether urine suggests a small-vessel glomerulonephritis alternative.

Management branches

First-line confirmationDefine the medium-vessel phenotype

Painful skin, nerve, renal-vascular, bowel or testicular features suggest PAN.

  1. Assess organ threat and map pulses, pressure, skin, nerve, abdominal and testicular findings, urine and cardiopulmonary absence or presence.
  2. Test hepatitis and infection, obtain CTA or MRA of involved territories and select accessible deep tissue for biopsy.
  3. Use catheter angiography when fine anatomy or embolisation is required and do not delay surgery for suspected bowel necrosis.

Key medicines

Prednisolone for severe PANUse 1 mg/kg orally once daily, commonly up to 60 mg/day, after intravenous methylprednisolone 500 mg–1 g daily for three days when an organ is critically threatened; taper with remission induction.Assess infection and HBV before prolonged therapy, monitor glucose, pressure, mood, eyes and bone, and provide prophylaxis according to total immune risk.
Intravenous cyclophosphamideA specialist pulse course may give 15 mg/kg intravenously at baseline, after two weeks and after four weeks, then continue at three-week intervals with age-, kidney- and cytopenia-based reductions.Monitor FBC, urine and infection and provide antiemetic and bladder protection. Discuss infertility preservation, teratogenicity, cumulative bladder cancer and later malignancy.
Open full textbook →Answer 2 questions
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • ACR Vasculitis Foundation PAN guidelineProfessional diagnostic, angiographic and severity-based treatment recommendations.
  • EASL 2025 hepatitis B guidelineAntiviral therapy and adjunctive immune treatment for major HBV extrahepatic disease.
  • NICE NG203 chronic kidney diseaseRenal and cardiovascular protection after vascular injury.
  • Entecavir UK product informationAdult dose, food, renal, HIV, withdrawal and reproductive safety.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom